Full Press Release Details
Astrana Health, Inc. Reports First Quarter
Company to Host Conference Call on Thursday,
May 7, 2026, at 2:30 p.m. PT/5:30 p.m. ET
ALHAMBRA, Calif., May 7, 2026 /PRNewswire/
-- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company")
(NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and
high-value care to all, today announced its consolidated financial results for the first quarter ended March 31, 2026.
"We had a strong start to 2026, delivering disciplined growth,
strong medical cost performance, continued operating leverage, and early performance from new full-risk contracts in line with our expectations,"
said Brandon Sim, President and Chief Executive Officer of Astrana Health. "In an increasingly dynamic healthcare environment, we
believe advantage will accrue to organizations that can integrate care delivery, data, and financial accountability into a single operating
system. Astrana has built exactly that: a proprietary healthcare operating platform that enables us to embed AI and workflow orchestration
directly into clinical and operational workflows across the enterprise. Combined with our longitudinal patient relationships and data
continuity, our infrastructure allows us to translate AI into durable clinical and economic value while continuing to improve patient
outcomes, operating efficiency, and scalability. We believe Astrana is well positioned to continue widening that advantage over time."
Financial Highlights for First Quarter Ended March 31, 2026:
All comparisons are to the three months ended
March 31, 2025 unless otherwise stated.
(1) See "Reconciliation of Net Income to EBITDA,
Adjusted EBITDA and Adjusted EBITDA Margin" and "Use of Non-GAAP Financial Measures" below for additional information.
(2) See reconciliation provided with the condensed consolidated statements of cash flow and "Use of Non-GAAP Financial Measures" below for additional information.
(3) See "Reconciliation of Net Income to Adjusted Net Income Attributable to Astrana and Adjusted EPS - Diluted" and "Use of Non-GAAP Financial Measures" below for additional information.
Recent Operating Highlights
Segment Results for three months ended March 31,
All comparisons are to the three months ended
March 31, 2025 unless otherwise stated.
| Three Months Ended March 31, 2026 | ||||||||||||||||||||||||
| (in thousands) | Care Partners | Care Delivery | Care Enablement | Intersegment Elimination | Corporate Costs | Consolidated Total | ||||||||||||||||||
| Total revenues | $ | 909,703 | $ | 85,077 | $ | 87,745 | $ | (117,425 | ) | $ | - | $ | 965,100 | |||||||||||
| % change vs. prior year quarter | 51 | % | 155 | % | 122 | % | ||||||||||||||||||
| Cost of services | 785,531 | 72,544 | 48,704 | (47,423 | ) | - | 859,356 | |||||||||||||||||
| General and administrative expenses | 72,546 | 14,374 | 17,259 | (69,974 | ) | 27,532 | 61,737 | |||||||||||||||||
| Depreciation and amortization | 12,170 | 1,122 | 1,629 | - | 558 | 15,479 | ||||||||||||||||||
| Total expenses | 870,247 | 88,040 | 67,592 | (117,397 | ) | 28,090 | 936,572 | |||||||||||||||||
| Income (loss) from operations | $ | 39,456 | $ | (2,963 | ) | $ | 20,153 | $ | (28 | ) (1) | $ | (28,090 | ) | $ | 28,528 | |||||||||
| % change vs. prior year quarter | (11 | )% | (5 | )% | 470 | % |
(1) Loss from operations for the intersegment elimination represents sublease income between segments. Sublease income is presented within other income, which is not presented in the table.
Astrana is providing the following guidance for
total revenue and Adjusted EBITDA for the quarter ending June 30, 2026 and reiterating guidance for the year ending December 31,
2026 based on the Company's existing business, current view of existing market conditions, and assumptions.
| Three Months Ending June 30, 2026 | Year Ending December 31, 2026 | |||||||||||||||
| Guidance Range | Guidance Range | |||||||||||||||
| ($ in millions) | Low | High | Low | High | ||||||||||||
| Total revenue | $ | 965 | $ | 1,000 | $ | 3,800 | $ | 4,100 | ||||||||
| Adjusted EBITDA | $ | 65 | $ | 70 | $ | 250 | $ | 280 | ||||||||
| Free cash flow | $ | 105 | $ | 132.5 |
See "Guidance Reconciliation of Net Income
to EBITDA and Adjusted EBITDA," "Guidance Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow,"
and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will
not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.
Conference Call and Webcast Information:
Astrana will host a conference call at 2:30 p.m. PT/5:30
p.m. ET today (Thursday, May 7, 2026), during which management will discuss the results of the first quarter ended March 31,
2026. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference
| U.S. & Canada (Toll-Free): | +1 (877) 858-9810 |
| International (Toll): | +1 (201) 689-8517 |
The conference call can also be accessed
slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website (https://ir.astranahealth.com/news-events/ir-calendar)
after issuance of the earnings release and will be furnished as an exhibit to Astrana's current report on Form 8-K to be filed
with the SEC, accessible at www.sec.gov.
Those who are unable to attend the live conference
call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.
Note About Consolidated Entities
The Company consolidates entities in which it
has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of
the voting rights, and variable interest entities ("VIEs") in which the Company is the primary beneficiary. Non-controlling
interests represent third party equity ownership interests in the Company's consolidated entities (including certain VIEs). The
amount of net income or loss attributable to non-controlling interests is disclosed in the Company's consolidated statements of
About Astrana Health, Inc.
Astrana Health is a physician-centric, AI-powered
healthcare company committed to delivering high-quality, patient-centered care. Built from the physician's perspective, Astrana combines
its scalable care delivery infrastructure, proprietary technology platform, and aligned provider networks to enable proactive, preventive
care at scale - improving patient outcomes, enhancing patient experiences, supporting provider well-being, and driving greater value across
the healthcare system.
supports more than 20,000 providers and approximately 1.55 million patients in value-based care arrangements through its affiliated provider
networks, management services organization, and integrated care delivery clinics spanning primary, specialty, and ancillary care. Together,
Astrana is building the healthcare system we all deserve - one that delivers better care, better experiences, and better outcomes for
all. For more information, visit www.astranahealth.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's guidance
for the quarter ending June 30, 2026 and the year ending December 31, 2026, ability to meet operational goals, ability to meet
expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality
and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing
environment, statements about the Company's liquidity, and successful completion and implementation of strategic growth plans, acquisition
strategy, and merger integration efforts, as well as statements regarding the material weakness in internal control over financial reporting
and the Company's ability to remediate such material weakness in a timely manner. Forward-looking statements reflect current views
with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations
and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or
may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties
and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the SEC,
including, without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31,
2025, and subsequent quarterly reports on Form 10-Q. Any forward-looking statements made by the Company in this release speaks only
as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether as
a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
FOR MORE INFORMATION, PLEASE CONTACT:
Carolyne Sohn, Investor Relations
ASTRANA HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
| March 31, 2026 | December 31, 2025 | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 478,383 | $ | 429,474 | ||||
| Receivables, net (including amounts from related parties) | 467,395 | 374,465 | ||||||
| Income taxes receivable | - | 1,799 | ||||||
| Other receivables | 28,017 | 26,385 | ||||||
| Prepaid expenses and other current assets | 25,647 | 26,264 | ||||||
| Loans receivable | 4,658 | 4,926 | ||||||
| Total current assets | 1,004,100 | 863,313 | ||||||
| Non-current assets | ||||||||
| Property and equipment, net | 59,546 | 57,332 | ||||||
| Intangible assets, net | 257,118 | 270,968 | ||||||
| Goodwill | 874,799 | 865,305 | ||||||
| Income taxes receivable, net of current portion | 26,220 | 26,220 | ||||||
| Loans receivable, net of current portion | 49,068 | 48,724 | ||||||
| Investments in other entities - equity method | 27,257 | 25,637 | ||||||
| Operating lease right-of-use assets | 33,933 | 35,738 | ||||||
| Other assets | 26,786 | 25,424 | ||||||
| Total non-current assets | 1,354,727 | 1,355,348 | ||||||
| Total assets (1) | $ | 2,358,827 | $ | 2,218,661 | ||||
| Liabilities, Mezzanine Deficit, and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 221,389 | $ | 195,912 | ||||
| Fiduciary accounts payable | 3,706 | 3,524 | ||||||
| Income taxes payable | 2,507 | - | ||||||
| Medical liabilities | 439,259 | 335,705 | ||||||
| Operating lease liabilities | 7,557 | 7,809 | ||||||
| Current portion of long-term debt | 47,865 | 47,865 | ||||||
| Other liabilities | 23,086 | 24,458 | ||||||
| Total current liabilities | 745,369 | 615,273 | ||||||
| Non-current liabilities | ||||||||
| Deferred tax liability | 7,399 | 5,491 | ||||||
| Operating lease liabilities, net of current portion | 30,006 | 31,552 | ||||||
| Long-term debt, net of current portion and deferred financing costs | 979,764 | 990,904 | ||||||
| Other long-term liabilities | 18,833 | 17,107 | ||||||
| Total non-current liabilities | 1,036,002 | 1,045,054 | ||||||
| Total liabilities (1) | 1,781,371 | 1,660,327 | ||||||
| Mezzanine deficit | ||||||||
| Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation ("APC") | (237,739 | ) | (234,962 | ) | ||||
| Stockholders' equity | ||||||||
| Preferred stock, $0.001 par value per share; 5,000,000 shares authorized; and zero shares issued and outstanding as of March 31, 2026 and December 31, 2025 | - | - | ||||||
| Common stock, $0.001 par value per share; 100,000,000 shares authorized, 48,946,399 and 48,885,358 shares issued and outstanding, excluding 10,695,758 and 10,571,011 treasury shares, as of March 31, 2026 and December 31, 2025, respectively | 49 | 49 | ||||||
| Additional paid-in capital | 477,508 | 470,863 | ||||||
| Retained earnings | 322,711 | 308,379 | ||||||
| Total stockholders' equity | 800,268 | 779,291 | ||||||
| Non-controlling interests | 14,927 | 14,005 | ||||||
| Total equity | 815,195 | 793,296 | ||||||
| Total liabilities, mezzanine deficit, and stockholders' equity | $ | 2,358,827 | $ | 2,218,661 |
(1) The Company's condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include (a) total assets of $1,317.1 million and $1,276.5 million as of March 31, 2026 and December 31, 2025, respectively, that can be used only to settle obligations of the Company's consolidated VIEs and (b) total liabilities of the consolidated VIEs of $394.5 million and $376.0 million as of March 31, 2026 and December 31, 2025, respectively, for which creditors do not have recourse to the general credit of the Company, the VIE's primary beneficiary. These VIE balances do not include $150.4 million of investment in affiliates and $24.4 million of amounts due from affiliates as of March 31, 2026, and $152.2 million of investment in affiliates and $58.3 million of amounts due from affiliates as of December 31, 2025, as these are eliminated upon consolidation and not presented within the condensed consolidated balance sheets.
ASTRANA HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Revenue | ||||||||
| Capitation, net | $ | 892,908 | $ | 583,963 | ||||
| Risk pool settlements and incentives | 12,486 | 14,491 | ||||||
| Management fee income | 15,685 | 2,310 | ||||||
| Fee-for-service, net | 37,831 | 14,890 | ||||||
| Other revenue | 6,190 | 4,736 | ||||||
| Total revenue | 965,100 | 620,390 | ||||||
| Operating expenses | ||||||||
| Cost of services, excluding depreciation and amortization | 859,356 | 549,061 | ||||||
| General and administrative expenses | 61,737 | 43,897 | ||||||
| Depreciation and amortization | 15,479 | 6,849 | ||||||
| Total expenses | 936,572 | 599,807 | ||||||
| Income from operations | 28,528 | 20,583 | ||||||
| Other (expense) income | ||||||||
| Income (loss) from equity method investments | 1,720 | (867 | ) | |||||
| Interest expense | (16,101 | ) | (7,308 | ) | ||||
| Interest income | 3,816 | 2,312 | ||||||
| Unrealized gain (loss) on investments | 1,084 | (44 | ) | |||||
| Other income (loss) | 662 | (5,072 | ) | |||||
| Total other expense, net | (8,819 | ) | (10,979 | ) | ||||
| Income before provision for income taxes | 19,709 | 9,604 | ||||||
| Provision for income taxes | 6,578 | 3,383 | ||||||
| Net income | 13,131 | 6,221 | ||||||
| Net loss attributable to non-controlling interests | (1,305 | ) | (471 | ) | ||||
| Net income attributable to Astrana Health, Inc. | $ | 14,436 | $ | 6,692 | ||||
| Earnings per share - basic | $ | 0.30 | $ | 0.14 | ||||
| Earnings per share - diluted | $ | 0.29 | $ | 0.14 | ||||
| Weighted average shares of common stock outstanding - basic | 48,853,678 | 48,470,682 | ||||||
| Weighted average shares of common stock outstanding - diluted | 49,054,135 | 48,850,666 |
ASTRANA HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | 13,131 | $ | 6,221 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 15,479 | 6,849 | ||||||
| Amortization of debt issuance cost | 1,134 | 691 | ||||||
| Share-based compensation | 9,895 | 7,811 | ||||||
| Non-cash lease expense | 2,005 | 1,287 | ||||||
| Deferred tax | 1,907 | (358 | ) | |||||
| Change in fair value of contingent consideration liabilities | 581 | 1,407 | ||||||
| Other | (2,564 | ) | 729 | |||||
| Changes in operating assets and liabilities, net of business combinations | 26,488 | (8,010 | ) | |||||
| Net cash provided by operating activities | 68,056 | 16,627 | ||||||
| Cash flows from investing activities | ||||||||
| Purchases of property and equipment | (4,000 | ) | (3,070 | ) | ||||
| Other | 1,156 | 676 | ||||||
| Net cash used in investing activities | (2,844 | ) | (2,394 | ) | ||||
| Cash flows from financing activities | ||||||||
| Dividends paid | (104 | ) | (5,455 | ) | ||||
| Borrowings on debt | - | 412,000 | ||||||
| Repayment of debt | (11,967 | ) | (428,232 | ) | ||||
| Deferred financing cost | - | (17,241 | ) | |||||
| Taxes paid from net share settlement of restricted stock | (1,172 | ) | (4,052 | ) | ||||
| Repurchase of treasury shares | (2,906 | ) | - | |||||
| Other | 189 | (1,190 | ) | |||||
| Net cash used in financing activities | (15,960 | ) | (44,170 | ) | ||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 49,252 | (29,937 | ) | |||||
| Cash, cash equivalents, and restricted cash, beginning of period | 434,045 | 289,101 | ||||||
| Cash, cash equivalents, and restricted cash, end of period | $ | 483,297 | $ | 259,164 | ||||
| Supplemental disclosures of cash flow information | ||||||||
| Cash paid for income taxes | (1) | $ | 4,338 | |||||
| Cash paid for interest | $ | 14,723 | $ | 7,360 | ||||
| Supplemental disclosures of non-cash investing and financing activities | ||||||||
| Right-of-use assets obtained in exchange for operating lease liabilities | $ | 350 | $ | 5,729 | ||||
| Dividend paid in the form of common stock | $ | - | $ | 21,935 |
(1) Following the adoption of ASC 2023-09 "Income Taxes (Topics 740): Improvements to Income Tax Disclosures", cash paid for income taxes is presented net of tax refunds, for the quarter ended March 31, 2026, under Item 1 of the Company's Quarterly Report on Form 10-Q.
The following table provides a reconciliation
of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total amounts
of cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows (in thousands):